COST-EFFECTIVENESS ANALYSIS OF APIXABAN COMPARED TO OTHER DOACS FOR PREVENTION OF STROKE IN AUSTRIAN ATRIAL FIBRILLATION PATIENTS

被引：0
|
作者：
Walter, E. [1 ]
Voit, M. [1 ]
Eichhober, G. [1 ]
机构：
[1] Inst Pharmaecon Res, Vienna, Austria
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV42
引用
收藏
页码：S548 / S548
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
    Dorian, Paul
    Kongnakorn, Thitima
    Phatak, Hemant
    Rublee, Dale A.
    Kuznik, Andreas
    Lanitis, Tereza
    Liu, Larry Z.
    Iloeje, Uchenna
    Hernandez, Luis
    Lip, Gregory Y. H.
    EUROPEAN HEART JOURNAL, 2014, 35 (28) : 1897 - 1906
  • [32] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTS
    de Andres-Nogales, F.
    Oyaguez, I
    Suarez, C.
    Lopez-Sendon, J. L.
    Gonzalez-Juanatey, J. R.
    Suarez, J.
    Polanco, C.
    VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [33] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
    Canal Fontcuberta, G.
    Escolar Albaladejo, G.
    Betegon Nicolas, L.
    de Salas-Cansado, M.
    Rubio-Rodriguez, D.
    Rubio-Terres, G.
    VALUE IN HEALTH, 2013, 16 (07) : A523 - A523
  • [34] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION PORTUGUESE PATIENTS
    de Andres-Nogales, F.
    Gay-Pobes, P. R.
    Ines, M.
    Polanco Sanchez, C.
    Alves, D.
    Oyaguez, I
    VALUE IN HEALTH, 2019, 22 : S549 - S550
  • [35] COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN FOR THE PREVENTION OF STROKE IN IRANIAN ATRIAL FIBRILLATION PATIENTS
    Keshavarz, K.
    Meshkini, Hashemi A.
    Nikfar, S.
    Ashkuh, M. S.
    Sanati, E.
    VALUE IN HEALTH, 2016, 19 (07) : A654 - A654
  • [36] Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia
    Ademi, Zanfina
    Pasupathi, Kumar
    Liew, Danny
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2015, 22 (03) : 344 - 353
  • [37] Cost-Effectiveness of Apixaban Compared to Other New Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation
    Rudakova, A. V.
    Tatarskiy, B. A.
    KARDIOLOGIYA, 2014, 54 (07) : 43 - 52
  • [38] Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
    de Jong, Lisa A.
    Groeneveld, Jessie
    Stevanovic, Jelena
    Rila, Harrie
    Tieleman, Robert G.
    Huisman, Menno, V
    Postma, Maarten J.
    van Hulst, Marinus
    PLOS ONE, 2019, 14 (09):
  • [39] COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN COMPARED TO WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN A MEDICARE POPULATION
    Ward, M. A.
    Biddle, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A121 - A121
  • [40] Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
    Hersi, Ahmad S.
    Osenenko, Katherine M.
    Kherraf, Sid Ahmed
    Aziz, Ayman Abdel
    Sambrook, Robert Joseph
    ANNALS OF SAUDI MEDICINE, 2019, 39 (04) : 265 - 278
12345